OncoBEAM RAS CRC assay regulatory update

Merck and Sysmex said the OncoBEAM RAS CRC assay received CE Mark approval to detect Ras mutations in patients with metastatic colorectal cancer (mCRC) and determine which patients would benefit from anti- EGFR treatment, including Merck’s Erbitux cetuximab. The companies said they plan to launch the blood-based, 34-mutation panel by year end in Europe, Asia, Latin America and Australia. ...